"Extrapulmonary Pneumocystosis in Patients Taking Aerosolised Pentamidine"

Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

"Extrapulmonary Pneumocystosis in Patients Taking Aerosolised Pentamidine"

Lancet (12/16/89) Vol. 2, No. 8677, P. 1454
Northfelt, Donald W.

Abstract: Because pentamidine received via aerosol does not result in systemic distribution, it cannot be expected to suppress extrapulmonary Pneumocystis carinii pneumonia (PCP) infection, writes Donald W. Northfelt of San Francisco General Hospital. A review of patients who received prophylactic aerosolized pentamidine and developed extrapulmonary PCP infection, writes Northfelt, reveals several common features: widely disseminated infection, often without concurrent pneumonia; long duration of AIDS; prolonged use of aerosolized pentamidine; and concurrent treatment with zidovudine (AZT). Aerosolized pentamidine and AZT in prolonged use, writes Northfelt, may allow for the emergence of more insidious subacute disorders such as extrapulmonary PCP. Prolonged surveillance, the researcher writes, is necessary to determine the incidence of extrapulmonary PCP and the need for systemic prophylaxis to prevent disseminated PCP in HIV-infected patients.

901216
AD901589

Copyright © 1990 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.